InfaCare’s Jaundice Drug Stannsoporfin Brings Efficacy, Safety Questions Into US FDA Panel
Executive Summary
Whether the single pivotal trial provides ‘substantial and highly persuasive evidence of effectiveness’ is a key question for advisory committee, although FDA also seeks advice on adequacy of the data to characterize adverse neurodevelopment outcomes; if approved, the heme oxygenase inhibitor could face a restrictive Risk Evaluation and Mitigation Strategy.
You may also be interested in...
At Stannsoporfin Advisory Committee, Talk Of Additional Studies Stirs Feasibility Doubts And High Emotions
InfaCare’s jaundice drug needs more neurodevelopmental outcome studies, US FDA committee says, but one panelist doubts feasibility of long-term follow-up; talk of additional studies leads to an unusual tongue-lashing from one of InfaCare's experts, who says he was 'stunned' by the committee’s conclusion that efficacy had not been shown.
InfaCare’s Stannsoporfin For Jaundice Rebuked By US FDA Panel
Uncertainties about clinical benefit and neurodevelopmental safety drive lopsided recommendation against approval; some advisory committee members say that even FDA’s REMS proposal wouldn't be enough to allow stannsoporfin to come to market without further studies.
Drugs For Severe Hyperbilirubinemia Could Face Long Development Program
FDA’s Gastrointestinal Drugs Advisory Committee notes difficulty in identifying endpoint during a March 13 meeting to discuss potential drug development pathways for the disease.